Cabometyx, Opdivo, Yervoy Triple Combo Shows Potential Benefits in Advanced HCC, Trial Data Show
News
A combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), with or without Yervoy (ipilimumab), induces clinically meaningful responses in people with advanced hepatocellular carcinoma (HCC) — the most common type of ... Read more